Roche has achieved CE Mark approval for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution, marking a significant advancement in diabetes management technology. This approval clears the way for the solution's availability to individuals aged 18 and older with type 1 and type 2 diabetes on flexible insulin therapy.
CEO of Roche Diagnostics, Matt Sause, highlighted the complexity of managing blood glucose levels for people with diabetes, involving numerous daily therapy decisions. The Accu-Chek SmartGuide CGM aims to address these challenges with predictive algorithms that predict glucose levels and detect patterns, aiding users in proactively managing their condition.
Despite the positive impact of CGM technology on glycemic control, a notable portion of diabetes patients still struggle to meet glycemic targets and experience frequent hypoglycemic episodes, including severe ones requiring medical intervention. Nighttime hypoglycemia particularly affects quality of life and increases anxiety among users.
Roche's Accu-Chek SmartGuide CGM solution operates through a sensor that transmits real-time glucose data to a mobile app. An integrated predictive app forecasts glucose trends over the next hours and identifies risks of hypoglycemia, including nocturnal episodes. Clinical evaluations have demonstrated high system accuracy and reliable predictive capabilities, meeting stringent performance criteria.
The solution integrates seamlessly with Roche's Accu-Chek® Care platform, enabling healthcare professionals to access comprehensive patient data for personalized therapy adjustments and improved outcomes. This holistic approach aims to empower individuals with diabetes to manage their condition effectively and live healthier lives.
Overall, Roche's Accu-Chek SmartGuide CGM solution represents a significant advancement in diabetes care, leveraging advanced technology to enhance predictive capabilities, mitigate risks, and support informed therapy decisions for better patient outcomes.